This product is an anti-blood suppository containing heparin sodium. Da
Heparin sodium is a low molecular weight heparin sodium derived from pig
intestinal mucosa with an average molecular weight of 5000.
Daheparin sodium enhances its inhibition of clotting factor Xa and thrombin mainly through antithrombin (AT), so as to play its antithrombotic role. The inhibitory effect of this product on enhancing the coagulation factor Xa was higher than that on prolonging the plasma coagulation time (APTT).
The effect of this drug on platelet function and platelet adhesion is less than that of heparin and therefore has only a small effect on primary hemostasis. Some of the antithrombotic properties of this product are thought to be mediated by the wall of the blood vessel or the fibrinolytic system.
The acute toxicity of da heparin sodium was much lower than heparin. The most obvious response repeated in toxicology studies was local bleeding at the injection site after large doses of injection. The incidence and extent of this reaction are dose-dependent and not cumulative.
Local bleeding reactions were associated with dose-dependent changes in anticoagulation, measured by APTT and anti-XA activity. At the same dose, there was no stronger osteopenia than heparin, and the two were similar. No organ toxicity was found regardless of the route of administration, dose and treatment period. No mutagenic reactions were found. No fetal toxicity or teratogenic effects during pregnancy or effects on fertility, perinatal or postpartum were found.